GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

 GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

Shots:

  • The P-III trial will assess adjuvanted CoVLP formulation (two doses of 3.75µg, administered 21 days apart) vs PBO in ~30,000 subjects initially in healthy adults (18-65yrs.), followed by elderly adults (65yrs.+) and adults with comorbidities
  • The US FDA and Health Canada have approved the initiation of the P-III study based on the positive P-II results which are expected to be available in Apr’21.
  • In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants. The US FDA has granted FTD to the vaccine on Feb 17, 2021

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: ABC 11

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post